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The Journal of Immunology
Antibody Stabilization of Peptide–MHC Multimers Reveals
Functional T Cells Bearing Extremely Low-Affinity TCRs
Katie Tungatt,* Valentina Bianchi,* Michael D. Crowther,* Wendy E. Powell,*
Andrea J. Schauenburg,* Andrew Trimby,* Marco Donia,† John J. Miles,*,‡
Christopher J. Holland,* David K. Cole,* Andrew J. Godkin,* Mark Peakman,x
Per Thor Straten,† Inge Marie Svane,† Andrew K. Sewell,*,1 and Garry Dolton*,1
Fluorochrome-conjugated peptide–MHC (pMHC) multimers are commonly used in combination with flow cytometry for direct ex
vivo visualization and characterization of Ag-specific T cells, but these reagents can fail to stain cells when TCR affinity and/or
TCR cell-surface density are low. pMHC multimer staining of tumor-specific, autoimmune, or MHC class II–restricted T cells can
be particularly challenging, as these T cells tend to express relatively low-affinity TCRs. In this study, we attempted to improve
staining using anti-fluorochrome unconjugated primary Abs followed by secondary staining with anti-Ab fluorochrome-
conjugated Abs to amplify fluorescence intensity. Unexpectedly, we found that the simple addition of an anti-fluorochrome
unconjugated Ab during staining resulted in considerably improved fluorescence intensity with both pMHC tetramers and
dextramers and with PE-, allophycocyanin-, or FITC-based reagents. Importantly, when combined with protein kinase inhibitor
treatment, Ab stabilization allowed pMHC tetramer staining of T cells even when the cognate TCR–pMHC affinity was extremely
low (KD >1 mM) and produced the best results that we have observed to date. We find that this inexpensive addition to pMHC
multimer staining protocols also allows improved recovery of cells that have recently been exposed to Ag, improvements in the
recovery of self-specific T cells from PBMCs or whole-blood samples, and the use of less reagent during staining. In summary, Ab
stabilization of pMHC multimers during T cell staining extends the range of TCR affinities that can be detected, yields consid-
erably enhanced staining intensities, and is compatible with using reduced amounts of these expensive reagents. The Journal of
Immunology, 2015, 194: 000–000.
F
luorochrome-conjugated peptide–MHC (pMHC) multimers
are now widely used in conjunction with flow cytometry
for identifying Ag-specific T cell populations in direct
ex vivo samples (1). The staining of T cells with multimerized
pMHC circumvents the need for cellular activation required by
other T cell detection methodologies and thereby allows detection
of cells that fail to activate or that do not respond with the effector
function(s) used for function-based profiling. pMHC multimer
staining is also compatible with T cell phenotyping directly ex
vivo by using a spectrum of fluorochrome-conjugated Abs specific
for other T cell markers. Our previous studies have demonstrated
that the binding affinity threshold for staining with pMHC class I
(pMHC I) tetramers is significantly higher than that required for
T cell activation (2). Thus, pMHC tetramers fail to stain all T cell
subsets that are capable of responding to any given pMHC Ag.
The disparity between the TCR affinity required for pMHC mul-
timer staining and that required for T cell activation is highlighted
when attempting to identify T cells specific for self-derived pep-
tides (antitumor and autoimmune T cells), which generally bear
TCRs that bind relatively weakly (KD 10–300 mM) (3–5). This
issue is further compounded when staining pMHC class II (pMHC
II)-restricted T cells as, unlike the CD8 molecule, the CD4 co-
receptor does not cooperate to aid TCR–pMHC binding (1, 6–12).
The importance of this issue was highlighted by Sabatino and
colleagues (13), who demonstrated that staining with pMHC II
tetramers ex vivo underestimated the lymphocyte choriome-
ningitis virus glycoprotein61–80 and myelin oligodendrocyte
glycoprotein35–55 CD4
+ T cell populations by 4- and 8-fold,
respectively. Demonstrations that pMHC tetramers can fail to
detect the majority of responding cells in polyclonal antiviral and
autoimmune T cell populations (13) highlight the pressing need to
extend pMHC multimer technology to a point where it can be used
to stain all T cells capable of responding to a given pMHC Ag (14,
15). Previously, we have described several improvements in
pMHC multimer technology that extend the range of TCR–pMHC
interactions that can be detected (1). The most promising of these
technologies include use of anti-coreceptor Abs that enhance,
*Institute of Infection and Immunity, Cardiff University School of Medicine, Uni-
versity Hospital, Cardiff CF14 4XN, Wales, United Kingdom; †Center for Cancer
Immune Therapy, Herlev University Hospital, DK-2730 Herlev, Denmark;
‡QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia;
and xDepartment of Immunobiology, King’s College London School of Medicine,
Guy’s Hospital, London SE1 9RT, United Kingdom
1A.K.S. and G.D. contributed equally to this work.
Received for publication July 14, 2014. Accepted for publication October 30, 2014.
G.D. was supported by Juvenile Diabetes Research Foundation award 17-2012-352
(to A.K.S. and M.P.). K.T. was supported by a Cardiff University Presidents Award.
V.B. was supported by Cancer Research Wales. J.J.M. is funded by an Australian
National Health and Medical Research Career Development Fellowship. A.K.S. is
a Wellcome Trust Senior Investigator. D.K.C. is a Wellcome Trust Career Develop-
ment Fellow.
Address correspondence and reprint requests to Dr. Andrew K. Sewell, Cardiff Uni-
versity School of Medicine, Henry Wellcome Building, Heath Park, Cardiff CF14
4XN, Wales, U.K. E-mail address: sewellak@cardiff.ac.uk
The online version of this article contains supplemental material.
Abbreviations used in this article: 1˚, primary; 2˚, secondary; APL, altered peptide
ligand; hTERT, human telomerase reverse transcriptase; ICS, intracellular cytokine
staining; MFI, mean fluorescence intensity; PFA, paraformaldehyde; PKI, protein
kinase inhibitor; pMHC, peptide–MHC; pMHC I, pMHC class I; pMHC II, pMHC
class II; PPI, preproinsulin; P/S, penicillin and streptomycin; RT, room temperature;
TIL, tumor-infiltrating lymphocyte.
This is an open-access article distributed under the terms of the CC-BY 3.0 Unported
license.
Copyright  2014 The Authors 0022-1767/14
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1401785
 Published December 1, 2014, doi:10.4049/jimmunol.1401785
 at Cardiff U
niv on January 7, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
rather than inhibit, staining (16, 17), use of protein kinase inhibitor
(PKI) during staining (18), and use of ultra-bright high-valency
reagents such as pMHC dextramers (15). Importantly, all of these
methodologies can be used in combination for synergistic effects.
In this study, we examined whether signal amplification via use of
Abs to pMHC multimers could be used for improved detection.
Our data revealed that simple addition of anti-multimer Ab during
pMHC tetramer or dextramer staining can result in substantial
improvements in staining intensity even when a log-fold lower
concentration of reagent was used. We anticipate that this im-
proved methodology will become widely adopted due to the large
potential cost saving and a substantial extension to the range of
TCR affinities that can be detected with pMHC multimers.
Materials and Methods
Cells
T cell clones/lines and tumor-infiltrating lymphocytes (TILs) were cultured
in RPMI 1640 media supplemented with penicillin and streptomycin (P/S),
L-glutamine, 10% FBS, 0.01 M HEPES buffer, nonessential amino acids,
sodium pyruvate (Life Technologies, Paisley, U.K.), 25 ng/ml IL-15
(PeproTech, Rocky Hill, NJ) (T cell clones and TILs only), and either
20 or 200 IU/ml IL-2 (aldesleukin, brand name Proleukin; Prometheus,
San Diego, CA), depending on the stage of culture. Tumor cells and sur-
rogate pancreatic b cells (19) were cultured in RPMI 1640 media sup-
plemented with P/S, L-glutamine, and 10% FBS (R10). Adherent cells
were detached from tissue culture flasks by gently rinsing the cells with
calcium and magnesium chloride–free Dulbecco’s PBS (Life Technolo-
gies), followed by incubation with Dulbecco’s PBS and 2 mM EDTA at
37˚C, until the cells detached.
We made use of the following HLA-A*0201 (HLA-A2)–restricted
CD8+ T cell clones: 1) ILA1, which is specific for the human telomerase
reverse transcriptase (hTERT)–derived peptide ILAKFLHWL (residues
540–548) (20) as well as four altered peptide ligands (APL), referred to as
8E, 4L, 5Y, and 3G, which bind to the ILA-1 TCR with varying affinities
(2, 21); 2) 1E6 and 3F2, which recognize the ALWGPDPAAA epitope
from preproinsulin (PPI: residues 15–24) and originate from the same
patient with type 1 diabetes (19); and 3) VB6G4.24, which recognizes the
heteroclitic peptide ELAGIGILTV (heteroclitic residue in boldface) from
Melan A (residues 26–35) and was derived from TILs of a patient with
malignant melanoma [patient MM909.24 (22)]. We also made use of the
HLA-DRB1*0101 (HLA-DR1)–restricted CD4+ clone DCD10, which
recognizes the PKYVKQNTLKLAT epitope from influenza A hemagglu-
tinin (residues 307–319) (23). T cell clones were routinely expanded by
restimulation with allogeneic PBMCs and PHA as previously described
(24), then cultured for at least 14 d before being used for staining, unless
stated otherwise.
Fresh blood samples were obtained by venipuncture from volunteers
(heparinized) or buffy coats (EDTA treated) from the Welsh Blood Service
in accordance with the appropriate ethical approval. PBMCs were isolated
by density centrifugation over an equal volume of Lymphoprep (Axis
Shields, Oslo, Norway). PBMCs were either used immediately or from
cryopreserved samples, with the latter being treated with 10–50 mg/ml
DNase-I (Roche, Burgess Hill, U.K.) for at least 20 min after thawing at
37˚C. We find that it is preferable to use fresh samples, as previously
frozen samples can exhibit higher background levels of staining with some
pMHC multimers. Cells were frozen in FBS with 10% DMSO using
a controlled-rate freezing device (CoolCell; Biocision, Larkspur, CA) as
per the manufacturer’s instructions and viable cell numbers enumerated by
trypan blue exclusion. Spiked samples were created by mixing clonal
T cells (104) with defrosted PBMCs (106), with the latter being cultured
(24-well plates at a density of 3 to 4 3 106/well in 2 ml R10) for 1 d prior
to staining. The spiked PBMCs were minimally HLA matched for the
restricting HLA of the spiking clone and treated as PBMC.
pMHC multimer assembly
Soluble biotinylated pMHC I and pMHC II were produced as previously
described (12, 25). Tetramers were assembled over five separate 20-min
steps with the successive addition of streptavidin-allophycocyanin or
–R-PE conjugates (Life Technologies) to monomeric pMHC at a molar
streptavidin:pMHC ratio of 1:4. Dextramer (Immudex, Copenhagen,
Denmark) PE, allophycocyanin, and FITC conjugates were assembled with
monomeric pMHC as previously described (15). Protease inhibitors (set 1;
Merck, London, U.K.) and PBS (tetramers) or dextramer buffer (15) were
added to give a final pMHC multimer concentration of 0.1 mg/ml (with
regards to the pMHC component), stored in the dark at 4˚C, and used
within 3 d of assembly. The same monomeric pMHC were used when tet-
ramers and dextramers were assembled for use within the same experiment.
PKI treatment
Cells were treated with the PKI dasatinib (Axon Medchem, Reston, VA) at
a final concentration of 50 nM (18) for 30 min at 37˚C and then stained with
tetramer or dextramer without washing or prechilling to 4˚C. It is impor-
tant to note that PKI is unstable when stored at 4˚C, so 1 mM DMSO
aliquots of PKI were stored at 220˚C. Then for each experiment, working
aliquots of 100 nM were prepared in PBS.
Primary and secondary Abs
Mouse anti-PE (clones PE001, BioLegend, London, U.K.; and eBioPE-
DLF, eBioscience, San Diego, CA), -allophycocyanin (clones APC003,
BioLegend; and eBioAPC-6A2, eBioscience), and -FITC (clone FIT-22;
BioLegend) primary (1˚) unconjugated mAbs were used at a concentra-
tion of 10 mg/ml (0.5 mg/test). Unless otherwise stated, the 1˚ Abs sourced
from BioLegend were used throughout this study. The goat anti-mouse
conjugated secondary (2˚) Abs (multiple adsorbed PE-, allophycocyanin-,
or FITC-conjugated Ig polyclonal; BD Biosciences, Oxford, U.K.) were
used at 2 mg/ml (0.1 mg/test). The fluorochrome conjugated to the 2˚ Abs
were matched to the fluorochrome used for the initial pMHC multimer
staining. Both anti-fluorochrome and anti-Ab Abs were spun at maximum
speed in a microcentrifuge for 1 min to remove any aggregates before
staining cells. The optimal amounts of 1˚ and 2˚ Abs were established
during this study using an Ab matrix on the 1E6 T cell clone. The matrix
covered a range of 1˚ and 2˚ Ab concentrations (0.25–2 mg and 0.025–0.2
mg, respectively), tested individually and in combination. The concentra-
tion used for this study was based upon the highest signal (1˚ and 2˚ Abs in
combination) to noise (2˚ alone) ratio of fluorescent intensity.
Cell staining and flow cytometry
The desired number of cells, which was typically 0.5–1 3 105 of a T cell
clone and 1–3 3 106 TILs, PBMCs, T cell line, or spiked samples, was
transferred to flow cytometry tubes. Cells were washed with buffer (PBS
with 2% FBS) before proceeding to PKI treatment or tetramer/dextramer
staining as required. Tetramer concentrations ranged from 0.02 to 2.4 mg
(0.4–48 mg/ml with respect to the monomeric pMHC concentration) per
stain in 50 ml buffer, and typically 0.3 or 0.5 mg (6 or 10 mg/ml) was used
unless stated otherwise. Dextramer was used at 0.3 mg (6 mg/ml) per stain.
Following tetramer/dextramer addition, cells were placed on ice and in the
dark for 30 min. All subsequent Ab staining of the cells was performed for
20 min on ice and in the dark. Post–pMHC multimer staining, the cells
were washed in buffer and labeled with anti-fluorochrome unconjugated 1˚
Ab, followed by two washes with buffer before the anti-Ab conjugated 2˚
Ab was added. Cells were washed with buffer then PBS and the violet
LIVE/DEAD Fixable Dead Cell Stain, Vivid (Life Technologies) added
and placed in the dark at room temperature (RT) for 5 min, and then Abs
against cell-surface markers were added directly without washing. Sam-
ples were prepared for flow cytometry by washing once in buffer and
resuspended in PBS or 2% paraformaldehyde (PFA). For whole-blood
samples, 0.1–0.125 ml heparanized blood was added to prealiquoted tet-
ramer in flow cytometry tubes and incubated for 10 min at RT, with 0.375–
0.5 ml blood being used per condition. A one-step staining approach was
adopted in which the anti-fluorochrome 1˚ Ab was added directly to the
tetramer staining for 15 min at 4˚C, followed by a mixture of Abs against
cell-surface markers and incubated for a further 15 min at 4˚C. RBCs were
lysed by incubating for 10 min at 37˚C with 2.5 ml lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, and 0.01 mM EDTA [pH 7.2]) and then washed
by the addition of 2 ml of PBS. Lysis was repeated where necessary and
samples were combined for the same condition and run immediately on the
flow cytometer or fixed with 2% PFA for 20 min on ice before two washes
with PBS. A dead stain was not used for the whole-blood samples, al-
though DNA binding reagents could easily be incorporated during the
staining protocol and may give tetramer stains with less background. The
following mAbs were used depending on each experiment: anti–CD8-PE
and anti–CD8-allophycocyanin/PE-vio770 (clone BW135/80; Miltenyi
Biotec, Bergisch Gladbach, Germany); anti–CD3-PerCP (clone BW264/
56; Miltenyi Biotec); anti–CD19-Pacific blue (clone HIB19; Bio-
Legend); and anti–CD14-Pacific blue (clone M5E2; BioLegend). Typi-
cally, PBMC, spiked, and whole-blood samples were gated on single,
viable (not for whole blood), CD192CD142CD3+ lymphocytes and
displayed in bivariate CD8 versus tetramer/dextramer plots. T cell clones
were typically gated on single, viable, CD8+ or CD4+ lymphocytes
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displayed as histograms of tetramer fluorescence. Data were acquired on
an FACSCanto II (BD Biosciences) and analyzed with FlowJo software
(Tree Star, Ashland, OR).
Intracellular cytokine staining assay
Cells were washed from culture medium and incubated in resting media
(RPMI 1640 supplemented with P/S, L-glutamine, and 5% FBS) for 24 h
prior to activation. Subsequently, cells were incubated at 37˚C for 4 h,
with and without (6) APCs, at a 1:1 ratio, in 2 ml resting media (24-well
culture plate with a total cell density of 3–6 3 106/ml) containing
GolgiStop and GolgiPlug (both from BD Biosciences), according to the
manufacturer’s instructions. Cells were then stained as above with
cognate or irrelevant tetramer, 1˚ and 2˚ Ab(s), viability dye, and Abs
against desired cell-surface markers. Cells were prepared for intracel-
lular cytokine staining (ICS) by incubation with Cytofix/Cytoperm (BD
Biosciences) according to the manufacturer’s instructions (including
wash steps), before staining for 20 min on ice with mouse anti-human
IFN-g–allophycocyanin Ab (clone 45-15; Miltenyi Biotec). Cells were
stored overnight (4˚C in the dark) in 2% PFA before flow cytometry and
data analysis.
[51Cr] release cytotoxicity assay
Target cells were labeled for 1 h at 37˚C with 30 mCi chromium (sodium
chromate in normal saline; PerkinElmer, Waltham, MA) per 1 3 106 cells,
washed with R10, and allowed to leach for a further hour at 37˚C in R10 to
remove any excess chromium from the cells. After chromium labeling,
target cells were washed and plated at 2000 cells/well in 96-well tissue
culture plates. T cells were added to give the desired T cell to target cell
ratio and a final volume of 150 ml R10. Target cells were also incubated
alone or with 1% Triton X-100 detergent to give the spontaneous and total
chromium released from the target cells, respectively. After 4 h of incu-
bation, at 37˚C and 5% CO2, the supernatants were harvested (10% of total
volume), mixed with 150 ml Optipahse supermix scintillation mixture
(PerkinElmer) 96-well polyethylene terephthalate plates (PerkinElmer),
sealed, and the amount of released chromium measured indirectly on
a 1450 Microbeta counter (PerkinElmer). The percentage of specific target
cell lysis by T cells was calculated according to the following formula:
(experimental release [with T cells and target cells] 2 spontaneous release
from target cells)/(total release from target cells 2 spontaneous release
from target cells) 3 100.
Tetramer decay assays
T cell clone (5 3 105) was pretreated with PKI then stained with cognate
tetramer 6 an anti-fluorochrome unconjugated 1˚ Ab 6 a conjugated 2˚
Ab. Cells were washed with staining buffer, supernatant aspirated, and
incubated with 10 mg anti–HLA-A2 Ab (clone BB7.2, allophycocyanin
conjugated; eBioscience) or diluted in 3 ml buffer and incubated at RT in
the dark. PKI was present throughout some of the decay assays. Cells were
sampled at the times indicated in the results section, washed with excess
buffer, and fixed with 2% PFA.
Results
Addition of an anti-fluorochrome Ab substantially improves the
staining and detection of T cells with tetramer
We have previously described an important disparity between the
TCR–pMHC affinity required for T cell activation and that re-
quired for effective capture of pMHC tetramers from solution (2).
This difference means that pMHC tetramers do not stain all Ag-
specific T cell populations (2) and represents a particular problem
when pMHC multimers are used to stain self-specific or pMHC
II–restricted T cells with weaker affinity TCRs (1, 3–5, 13). We
made use of the ILA1 T cell clone that recognizes the HLA-A2–
restricted hTERT-derived peptide ILAKFLHWL. This hTERT
peptide is not naturally presented at the tumor cell surface (20)
and therefore provides a model system that is uncomplicated by
the possibility of a natural ligand. We have previously character-
ized a wide range of APL that act as agonists of the ILA1 T cell
and that range in affinity for the ILA1 TCR from KD ∼3 mM to KD
∼2 mM by surface plasmon resonance while binding to HLA-A2
equally well (2, 21). The ILA1 T cell system therefore enables the
TCR–pMHC affinity to be varied, whereas other variables such as
surface density of TCR and CD8 remain identical. Two of the
weaker APL in this system, 4L and 5Y, bind with a KD of 117 and
∼250 mM, respectively, and provide a good model for weakly
binding autoimmune TCRs. A further APL, 8E, still acts as a good
agonist of ILA1 T cells when supplied exogenously at a concen-
tration of 1 mM (2, 21) yet binds to the TCR with a KD ∼2 mM by
extrapolation of response units from surface plasmon resonance
experiments. Previously, we have devised a number of novel
techniques that lower the detection limit of pMHC multimer
staining. These include CD8-enhanced tetramers (10) and the use
of a PKI to prevent the internalization of TCRs from the cell
surface that have not productively captured pMHC multimer from
solution (18). The use of PKI considerably enhanced the range of
TCR affinities amenable to detection with pMHC tetramers (18).
When pMHC multimers are used in conjunction with PKI, the
multimers remain at the cell surface (15, 18). We reasoned that, in
the presence of PKI, pMHC multimers would be available for
further signal amplification using fluorochrome-conjugated Abs.
We therefore set up a staining protocol as shown in Fig. 1 that
included combinations of an anti-PE unconjugated 1˚ and anti-Ab
PE-conjugated 2˚ Abs as indicated. Initial experiments were
conducted using the weak ILA1 ligand HLA-A2–ILALFLHWL
FIGURE 1. Schematic representation of the test and control conditions used in this study. Alongside a standard pMHC multimer (tetramer or
dextramer) staining protocol (test 1), the binding of a mouse anti-fluorochrome unconjugated 1˚ Ab to the pMHC multimer associated fluorochrome
followed by a goat anti-mouse conjugated 2˚ Ab (test 2) was tested to see whether the fluorescence intensity of pMHC multimer staining could be
improved. A number of controls were performed: control 1: pMHC multimer with 1˚ Ab; control 2: pMHC multimer with 2˚ Ab; control 3: 1˚ Ab alone;
control 4: 2˚ Ab alone; control 5: 1˚ and 2˚ Abs in combination; and control 6: unstained. The color coding for tests 1 + 2 and controls 1 + 2 + 6 is used
throughout this study.
The Journal of Immunology 3
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(4L; KD = 117 mM). Tetramers of the weak 4L ligand barely
stained the ILA1 T cell clone in the absence of 50 nM PKI
(Fig. 2A). Addition of PKI enhanced staining by .6-fold. Further
inclusion of 1˚ and 2˚ Abs enhanced staining by ∼20-fold in the
absence of PKI and by ∼6-fold in the presence of PKI (Fig. 2A).
These results show that inclusion of Ab stabilization can have
marked effects on staining even when PKI is not included to
preclude TCR internalization. The additional increase in mean
fluorescence intensity (MFI) observed using anti-pMHC multimer
Ab in the presence of PKI confirmed that these two techniques
could be used in combination. Moreover, there was a 10-fold
enhancement in staining with tetramer and 1˚ Ab compared with
staining with tetramer alone (conditions: control 1 and test 1 in
Fig. 1, respectively). pMHC tetramer staining in the presence of
the 1˚ Ab was also almost four times brighter in the presence of
PKI. This substantial increase in pMHC tetramer staining in the
presence of a 1˚ Ab, but in the absence of any further fluoro-
chrome provided by a 2˚ Ab staining, was highly unexpected. We
next studied this unanticipated large increase in MFI afforded by
simple addition of anti-fluorochrome Ab during pMHC tetramer
staining by examining recovery of the ILA1 clone spiked into an
HLA-A2+ PBMC sample using tetrameric forms of a number of
different APL (Fig. 2B). Complete recovery of spiked ILA1
T cells was achieved in all cases when the 3G ligand (KD ∼3 mM)
was used (considered as 100% recovery). Only 71% of the cells
were recovered with pMHC tetramers of the cognate, hTERT-
derived HLA-A2–ILAKFLHWL ligand (KD ∼35 mM) in the ab-
sence of PKI treatment. This was increased to full recovery when
either PKI or 1˚ Ab were included. The greatest fluorescence in-
tensity was seen when both PKI and 1˚ Ab were included. The
effects of including 1˚ Ab during pMHC tetramer staining became
even more exaggerated with the 4L ligand (KD = 117 mM) in
which recovery with normal tetramer staining in the absence of
PKI treatment or Ab stabilization was extremely poor (6%). With
FIGURE 2. An anti-fluorochrome unconjugated Ab greatly enhanced the staining of T cells with tetramers when TCR–pMHC affinity is weak. (A) ILA1
hTERT-specific CD8+ T cells 6 50 nM PKI were stained with HLA-A2 PE-conjugated tetramers, assembled with the 4L peptide (KD = 117 mM) or
irrelevant (HLA-A2–ALWGPDPAAA, PPI) tetramers. Cells were stained with tetramers alone or with an anti-PE unconjugated 1˚ Ab, a 2˚ PE-conjugated
Ab, or 1˚ + 2˚ Abs together. The MFI is shown for each histogram. (B) In a separate experiment, the ILA1 CD8+ clone was spiked in to PBMCs from an
HLA-A2+ donor (used from frozen), treated6 PKI, and stained with PE-conjugated tetramers folded with cognate and APL agonists of the ILA1 clone (KD [mM]
shown in parentheses) or irrelevant epitope (as in A). Tetramers were used alone or in combination with anti-PE unconjugated 1˚ Ab. 2˚ Ab was not used in
this experiment to highlight the unexpected effect of 1˚ anti-fluorochrome Ab. The percentage recovery of gated cells is displayed in the inset and was
determined relative to the proportion of cells that stained with the 3G variant (considered 100%) after subtracting any background seen with the PPI
tetramer. Display is based on viable CD3+CD142CD192 cells.
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the 5Y ligand (KD ∼250 mM), full recovery was only achieved
when tetramer was used with PKI and 1˚ Ab in combination
(Fig. 2B). Remarkably, full recovery of ILA1 clone was still
possible when tetramers of the 8E ligand (KD ∼2 mM) were used
in conjunction with PKI and 1˚ Ab. In the past, we have failed to
recover cells using the 8E ligand using even our best technology to
date of PKI treatment in conjunction with higher valency, ultra-
bright, pMHC dextramers (15). Thus, the simple technology de-
scribed in this study extends the range of TCR–pMHC interactions
that are amenable to detection using pMHC multimers beyond the
current limit possible for these reagents.
Anti-fluorochrome Abs alone or in combination with
conjugated secondary Abs substantially improve staining of
autoimmune T cells with pMHC tetramers
We next looked at whether the increase in the MFI of staining with
pMHC tetramers observed with the ILA1 model system was ap-
plicable with other T cells and with pMHC multimers conjugated
to other fluorochrome molecules. For these experiments, we used
the 1E6 T cell clone that exhibits glucose-dependent killing of HLA-
A2+ human pancreatic b-cells and was derived from a patient with
type 1 diabetes (19). 1E6-mediated killing occurs via the PPI-
derived peptide ALWGPDPAAA presented by the disease risk al-
lele HLA-A2 (19). The 1E6 TCR binds to its cognate HLA-A2–
ALWGPDPAAA with a KD of .250 mM (26, 27). Fig. 3A shows
results with both PE and allophycocyanin reagents using anti-
fluorochrome unconjugated 1˚ Ab clones PE001 and APC003,
respectively. Inclusion of a 1˚ Ab and further fluorescence en-
hancement with anti-Ab conjugated 2˚ Ab increased the MFI of
staining by ∼4-fold and .5-fold for the PE and allophycocyanin
staining, respectively. In both cases, and as seen in the ILA1
system (Fig. 2A), the majority of this increase in fluorescence
intensity was apparent in the absence of a 2˚ Ab. Thus, inclusion
of a 1˚ Ab during pMHC tetramer staining can substantially in-
crease the intensity of staining of an autoimmune T cell clone with
pMHC tetramer. We also tested another anti-PE 1˚ Ab (eBioPE-
DL; BioLegend) and an anti-allophycocyanin 1˚ Ab (eBioAPC-
6A2; BioLegend), which gave increases of 3.5- and 2.4-fold, re-
spectively in the absence of a 2˚ Ab (data not shown). Similar
levels of enhancement were also observed with FITC-conjugated
reagents (dextramer FITC with corresponding reagents, data not
shown), showing that the substantial benefits afforded by addition
of anti-fluorochrome and anti-Ab Abs when staining cognate
autoimmune T cells are generally applicable and evident regard-
less of which fluorochrome is used.
Anti-fluorochrome Abs alone or in combination with
conjugated secondary Abs enhance staining of CD4 T cells
with pMHC II tetramers
The weaker average affinity of TCRs derived from MHC II–re-
stricted T cells (3) and lack of coreceptor help from CD4 (1)
means that it is generally more difficult to stain cognate T cells
with pMHC II tetramer than pMHC I tetramers (28), and pMHC II
tetramers have been shown to miss the majority of Ag-specific
T cells in polyclonal antiviral and autoimmune populations (13).
Given this limit in visualization, we next examined whether in-
clusion of anti-fluorochrome and anti-Ab Abs could be beneficial
in the pMHC II tetramer setting. For these experiments, we made
use of the HLA-DR1–restricted, influenza-specific T cell clone
DCD10. This antiviral T cell clone stains reasonably well with
cognate tetramer, with MFIs of 528 and 199 for the PE and
allophycocyanin reagents, respectively (Fig. 3B). Addition of an
anti-PE or -allophycocyanin unconjugated 1˚ Ab, used alone or in
combination with an anti-Ab conjugated 2˚ Ab enhanced the
staining of this T cell clone by 1.7- and 2.8-fold for PE reagents
and 1.6- and 3.3-fold for allophycocyanin reagents, respectively.
Thus, stabilization of pMHC II tetramers can improve the inten-
sity of cell staining with these reagents.
Ab stabilization illuminates low-affinity T cells otherwise
undetected by conventional tetramer staining and with lower
concentrations of tetramer
We next examined the effect of 1˚ and 2˚ Abs on pMHC tetramer
staining of the tumor-specific CTL clone VB6G4.24 that was
grown from the TILs derived from a patient with stage IV ma-
lignant melanoma (22). This clone efficiently kills the patient’s
autologous tumor even at low E:T ratios but does not stain by
conventional pMHC tetramer staining even when high amounts of
reagent were used (Fig. 4A). Tetramer staining of this clone was
negligible even with 2.4 mg of tetramer (with respect to the pMHC
component). Addition of an anti-PE unconjugated 1˚ Ab enabled
staining of this clone with most of the cognate pMHC tetramer
amounts tested and as low as 0.6 mg (with respect to the pMHC I
component) of tetramer. Further inclusion of an anti-Ab PE-
conjugated 2˚ Ab doubled the staining observed with the 1˚ Ab,
but as before, the majority of the enhancement in MFI was pro-
vided by inclusion of the 1˚ Ab alone.
FIGURE 3. Enhanced tetramer staining of an autoimmune T cell and an
MHC II–restricted T cell with anti-fluorochrome unconjugated and second-
ary conjugated Abs. (A) PKI-treated CD8+ T cell clone 1E6 was left
unstained or stained with PE and allophycocyanin-conjugated cognate HLA-
A2–ALWGPDPAAA (PPI) cognate and HLA-A2–ELAGIGILTV (Melan-A)
irrelevant tetramers, alone or with an anti-fluorochrome unconjugated 1˚
Ab 6 PE- or allophycocyanin-conjugated 2˚ Ab. (B) The CD4+ T cell clone,
DCD10, was left unstained or stained from culture with cognate HLA-DR1–
PKYVKQNTLKLAT (hemagglutinin of influenza) or irrelevant HLA-DR1–
DRFYKTLRAEQASQ (p24 Gag of HIV) PE- and allophycocyanin-conju-
gated tetramer as described in (A). MFIs are shown at the right of each graph.
The Journal of Immunology 5
 at Cardiff U
niv on January 7, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
Tetramers are most commonly used to stain antipathogen CD8+
T cells and have excelled for such applications (1, 29, 30). The TCRs
of CD8+ T cells raised against non–self-peptides tend to bind with
relatively strong affinity to their cognate pMHC Ag (KD 0.1–10 mM)
(3, 5, 31). We used tetramers to stain CMV-specific T cell pop-
ulations directly ex vivo and showed that inclusion of Ab allowed
full recovery of CMV-specific T cells from PMBC samples even
when .300-fold lower concentrations of pMHC tetramer were used
(just 3 ng with respect to pMHC). CMV-specific T cells could not be
detected as a separate distinct population of cells in the absence of
Ab when this amount of pMHC tetramer was used for staining
(Fig. 4B). Thus, the methodology described in this study allows
recovery of T cells with dramatically lower amounts of pMHC
multimer regardless of the TCR–pMHC affinity and is compatible
with ex vivo staining of PBMC. Lower concentrations of tetramer
could also be used when recovering the 1E6 PPI-specific clone from
spiked HLA-A2+ PBMC samples. Addition of a 1˚ Ab resulted in
recovery of .80% of the 1E6 cells even when 25-fold less pMHC
tetramer was used. Inclusion of a 2˚ Ab allowed full recovery of
cells, even when 25-fold less tetramer was used (data not shown).
Ab stabilization of pMHC tetramer and dextramers gives
superior recovery of T cells from multiple sources
We next compared pMHC multimer staining of a T cell line, TILs,
and PBMC samples using the following conditions: 1) pMHC
multimer alone (test 1, Fig. 1); 2) pMHC multimer + anti-PE
unconjugated 1˚ Ab (control 1, Fig. 1); and 3) pMHC multimer +
the 1˚ Ab + anti-Ab PE-conjugated 2˚ Ab (test 2, Fig. 1) (Fig. 5).
Fig. 5A shows classic tetramer staining of an HLA-A2–restricted
influenza matrix-specific T cell line. As expected, the cognate
CD8+ T cells in this antiviral line stain well with tetramer. Nev-
ertheless, inclusion of a 1˚ Ab during staining almost doubled the
MFI and resulted in recovery of a ∼25% greater population of
cells. Further inclusion of a 2˚ Ab resulted in a further minor
increase in both MFI and percent population recovered. We next
applied the same conditions in the presence of PKI for staining of
HLA-A2–ELAGIGILTV-specific cells in TILs expanded from
a melanoma lesion (Fig. 5B). A total of 2.3% of the cells in these
TILs stained with Melan-A–specific pMHC tetramer. The size of
this population almost doubled when 1˚ Ab was included in the
protocol. The population recovered increased from 3.9 to 4.9%
when a 2˚ Ab was also included. In an independent assay using the
same TILs, the Melan-A specific T cell population segregated into
two clean populations when 1˚ and 2˚ Abs were included with
tetramer (Supplemental Fig. 1A). The VB6G4.24 T cell clone
shown in Fig. 4A was cloned from these TILs and is effective at
killing patient autologous tumors. This clone does not stain with
pMHC tetramer (Fig. 4A), so we assume that this clone is one of
the T cell clonotypes that fails to stain using tetramer alone in the
presence of PKI in Fig. 5B. Importantly, staining can be recovered
FIGURE 4. Anti-fluorochrome and secondary Abs
enable staining of weak-avidity T cells at lower
concentrations of tetramer. (A) The CD8+ VB6G4.24
T cell clone, grown from TILs from a malignant
melanoma patient, kills autologous tumor (top left
panel). The clone was stained with various amounts
of PE-conjugated cognate HLA-A2–ELAGIGILTV
(Melan-A) and irrelevant HLA-A2–ALWGPDPAAA
(PPI) tetramers. Fresh cells were left unstained or
stained with tetramer alone or with an anti-PE un-
conjugated 1˚ Ab 6 PE conjugated 2˚ Ab. The bot-
tom left panel shows the MFI of tetramer staining,
which is shown in the histograms (right panel). (B)
Fresh HLA-A2+ PBMC was stained with HLA-A2–
NLVPMVTAV (pp65 of CMV, top panel) or PPI
(bottom panel) PE-conjugated tetramers. Cells
stained with 0.003 mg were either stained with tet-
ramer alone or tetramer with a combination of 1˚ and
2˚ Abs, as described in (A). The proportion of cells
that stained with 0.003 mg of tetramer is expressed
as a percentage (inset) of the cells that stained with
1 mg of tetramer after subtraction of any background
seen with the PPI tetramer (bottom panel). PBMC
were stained for viability and Abs against CD8,
CD3, CD14, and CD19. No pretreatment with PKI
was used throughout.
6 Ab CROSS-LINKING ADVANCES pMHC MULTIMER STAINING
 at Cardiff U
niv on January 7, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
when 1˚ Ab and 1˚ + 2˚ Abs were included in the staining pro-
tocol. Enhanced tetramer staining was also seen when tumor-
specific T cells were relatively abundant. The aforementioned
TILs were enriched for Melan-A–specific cells by coculture with
autologous tumor for 5 d. Twice as many cells were stained with
Melan-A tetramers when 1˚ and 2˚ Abs (9.4% versus 18.9%) were
included, which represents a considerable increase in the number
of T cells being detected (Fig. 5C). Thus, pMHC tetramer staining
in the absence of Ab stabilization can fail to recover effective
cognate CD8+ T cells resulting in a large underestimation of the
size of an Ag-specific T cell population. This large underestima-
tion of effective, Ag-specific CD8+ T cells with pMHC I tetramer
is in accordance with a previous study that showed that most Ag-
specific CD4+ T cells could not be detected by pMHC II tetramer
staining of ex vivo samples (13).
pMHC multimers are most commonly used for detecting Ag-
specific T cell populations directly ex vivo. To compare various
methodologies available in this context, we took advantage of the
fact that there is a relatively large population of naive T cells in
HLA-A2+ individuals that recognize a commonly used variant of
a self-peptide from the Melan-A protein (sequence ELAGI-
GILTV) due to a hardwired germline-encoded recognition motif
(32, 33). Some of these self-specific CD8+ T cells can be detected
by regular tetramer staining (Fig. 5D). The size of this population
increases from 0.03% of CD3+CD8+ cells to 0.09 and 0.11% of
cells when 1˚ Ab and 1˚ + 2˚ Abs were included, respectively. We
recently used this system to show that pMHC dextramers were
better at recovering low-avidity T cells when compared with
pMHC tetramers, with the best recoveries seen when dextramers
were used in the presence of PKI (15). The same effect was also
observed in this study in which use of pMHC dextramer gave 6.6-
fold more cells being recovered than with the equivalent pMHC
tetramer alone in the absence of PKI and 5.2-fold in the presence
of PKI (Fig. 5D). We also tested the effect of Ab with pMHC
FIGURE 5. Ex vivo staining and detection of T cells is improved by the addition of an anti-fluorochrome and conjugated secondary Ab to standard
pMHC multimer staining protocols. (A) AT cell line primed with GILGFVFTL peptide from the influenza virus (flu) was treated with PKI and stained with
cognate HLA-A2 PE-conjugated cognate and control (HLA-A2-RLGPTLMCL from MG50 protein) tetramers (Tet), alone or in combination with anti-PE
unconjugated 1˚ Ab 6 a PE-conjugated 2˚ Ab. (B) TILs from an HLA-A2+ metastatic melanoma patient were treated with PKI and stained with HLA-A2–
ELAGIGILTV (Melan-A) or HLA-A2–ALWGPDPAAA (PPI) PE-conjugated tetramers and Abs as in (A). (C) The staining described in (B) was performed
on TILs that had been cultured with autologous tumor for 5 d. (D) HLA-A2+ PBMCs taken directly ex vivo were incubated 6 PKI and stained with HLA-
A2–ELAGIGILTV or HLA-A2–ILAKFLHWL (hTERT) PE-conjugated tetramers or dextramers (Dex) and Abs as described in (A). Samples were mini-
mally stained for viability, CD3, and CD8, with CD14 and CD19 also being stained in (C). The tetramer+ cells are expressed as a percentage of total cells (A
and B) or CD8+ cells (C) and the MFIs are shown (inset).
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dextramers, which increased recovery from 0.20% for dextramer
alone, to 0.33 and 0.36% when 1˚ Ab and 1˚ + 2˚ Abs were in-
cluded, respectively. In the presence of PKI, the recovery of cells
increased from 0.68% (dextramer alone) to 1.06 and 1.53% when
1˚ Ab and 1˚ + 2˚ Abs were included. In accordance with our
earlier results, higher numbers of CD8+ T cells stained with
pMHC dextramer than with pMHC tetramer, reflecting the ability
of these higher valency reagents to stain T cells bearing lower-
affinity TCRs. Optimal recovery was seen with PKI + pMHC
dextramer + 1˚ + 2˚ Abs. The population recovered using this
combination was 50-fold greater than could be recovered with
pMHC tetramer alone, with no PKI, and 11-fold greater when
pMHC tetramer was used with PKI. Staining of PKI-treated
PBMCs from a second donor with Melan-A dextramers + 1˚ +
2˚ Abs recovered 11-fold more cells than Melan-A tetramers alone
(Supplemental Fig. 1B). Overall, in terms of cellular recovery and
regardless of PKI treatment, pMHC dextramer + 1˚ + 2˚ Ab .
pMHC dextramer + 1˚ Ab. pMHC dextramer. pMHC tetramer +
1˚ + 2˚ Abs . pMHC tetramer + 1˚ Ab . pMHC tetramer.
Ab stabilization is compatible with whole-blood staining with
pMHC tetramers
We next tested the compatibility of Ab stabilization when staining
whole blood with pMHC tetramers. Blood samples from two HLA-
A2+ healthy donors were stained with four different pMHC tet-
ramers as described in the Materials and Methods. Donor 1 had
populations of CD8+ T cells that stained with HLA-A2-
GILGFVFTL (influenza) and HLA-A2–ELAGIGILTV (Melan-A)
tetramers with MFIs of 2334 and 1032, respectively, for the
gates shown in Fig. 6. These MFIs increased to 7276 and 4095
when a 1˚ anti-PE Ab was included, and the number of cells
staining with the ELAGIGILTV Melan-A–specific reagent dou-
bled. Donor 2 had populations of T cells that stained with HLA-
A2–CLGGLLTMV (EBV) and HLA-A2-NLVPMVTAV (CMV)
tetramers, with the 1˚ Ab increasing the MFI of tetramer staining
from 613 to 2115 and 674 to 5774, respectively. We conclude that
Ab stabilization of pMHC multimers is compatible with whole-
blood staining protocols.
Ab stabilization of pMHC tetramers improves recovery of
T cells that have recently been exposed to Ag
Ag engagement is known to trigger and downregulate TCR from
the T cell surface (34) and makes pMHC multimer staining more
difficult due to low TCR density (15). This aspect could be
problematic if staining pathogen-specific T cells during acute or
chronic infections. It is also likely that self-specific T cells, be
they antitumor T cells in TILs or of autoimmune origins, will have
recently encountered their cognate Ag in vivo prior to staining. We
mimicked this situation by exposing TIL to autologous tumor or
autoimmune T cells to target cells endogenously producing cog-
nate self-Ag prior to examining cellular recovery with pMHC
multimers. TILs from an HLA-A2+ metastatic melanoma patient
were incubated with brefeldin A and monensin 6 autologous tu-
mor for 4 h prior to staining with Melan A tetramer and intra-
cellularly with anti–IFN-g Ab (Fig. 7A). After exposure to tumor,
tetramer alone, tetramer with an anti-PE unconjugated 1˚ Ab 6
anti-Ab PE-conjugated 2˚ Ab recovered 29, 62, and 80% of the
ELAGIGILTV-specific T cells that could be recovered without
prior exposure to tumor, respectively. We also examined staining
of the 1E6 PPI-specific T cell clone after incubation with K526
cells expressing HLA-A2 or K526 cells expressing HLA-A2 and
PPI, with the latter termed "surrogate pancreatic b cells." Staining
of 1E6 cells was very poor with tetramer alone postexposure
to K526 cells expressing the cognate Ag compared with when
FIGURE 6. Ab stabilization is compatible with whole-
blood staining with pMHC multimers. Fresh heparinized
whole blood from two HLA-A2+ donors was treated with
PKI then added to prealiquoted PE- (donor 1) or allo-
phycocyanin-conjugated (donor 2) tetramers. Both donors
were stained with HLA-A2–ALWGPDPAAA (PPI) tetra-
mer. Donor 1 was stained with HLA-A2–GILGFVFTL
(influenza [Flu]) and HLA-A2–ELAGIGILTV (Melan-A)
tetramers and donor 2 with HLA-A2–CLGGLLTMV
(EBV) and HLA-A2–NLVPMVTAV (CMV) tetramers.
Anti-PE or allophycocyanin unconjugated 1˚ Ab was
added directly to the cells, followed by a mixture of Abs
against cell-surface markers (CD19, CD14, CD3, and
CD8) before lysis of RBCs. A total number of 33 105 and
1 3 105 CD3+CD192CD142 cells were acquired from 0.5
ml and 0.375 ml of whole blood for donors 1 and 2, re-
spectively. The percentage of cells residing within the gate
and the MFI of this population are shown for each plot.
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1˚ Ab 6 2˚ Ab, were used (11, 80, and 90% of the cells stained
with each condition, respectively; Fig. 7B). This staining pattern
was reflected when 1E6 cells that had been incubated with K526
cells 6 cognate Ag were spiked into HLA-A2+ PBMC. Tetramer +
1˚ + 2˚ Abs was able to recover 94% of the cells that had been
exposed to K526 surrogate b cells, whereas recovery with tetramer +
1˚ Ab or tetramer alone was 35 and 0.2%, respectively (Fig. 7C).
These results confirm our previous findings that tetramers are poor at
recovering T cells following exposure to cognate Ag (15) but show
that the inclusion of 1˚ or 1˚ + 2˚ Abs against tetramer as described
in Fig. 1 can reverse most of this effect and enable effective T cell
staining (Fig. 7B, 7C).
Ab stabilizes pMHC tetramer at the T cell surface
When we initially saw that inclusion of an unconjugated anti-
fluorochrome Ab dramatically improved theMFI of staining during
pMHC tetramer staining, we considered the possibility that the
1˚ Ab might function by somehow stabilizing the fluorochrome
and/or enhancing its ability to emit detectable fluorescence. Sub-
sequent experiments showed the same affect with different Ab
clones and MFI enhancements with anti-allophycocyanin or anti-
FITC Abs and appropriate fluorochrome-conjugated pMHC mul-
timers (Fig. 3 for allophycocyanin data, FITC not shown). We
further tested the stabilization of fluorochrome hypothesis by us-
ing an unconjugated 1˚ Ab against the streptavidin component of
FIGURE 7. Activated T cells can be
detected when tetramers were used with
anti-fluorochrome and secondary Abs. (A)
TILs from a HLA-A2+ metastatic mela-
noma patient were incubated with bre-
feldin A and monensin, 6 autologous
tumor. Cells were stained with cognate
HLA-A2–ELAGIGILTV (Melan A) or
HLA-A2–ALWGPDPAAA, PPI) PE-con-
jugated tetramers (Tet) alone or further
labeled with an anti-PE unconjugated
1˚ Ab 6 PE conjugated 2˚ Ab. Cells were
also stained intracellularly for IFN-g. Tet-
ramer+ cells (red box) from the TILs with
autologous tumor are expressed as a per-
centage (inset, top panel) of tetramer+ cells
(Tet + 1˚ + 2˚ Abs) from the TILs alone
after subtracting the number of gated cells
seen with the PPI tetramer (bottom panel).
(B) The CD8+ T cell clone 1E6, specific for
ALWGPDPAAA from PPI, was incubated
with K562-A2+ or K562-A2+ that express
PPI (the latter process and present the
cognate epitope). At 24 h postincubation,
the cells were treated with 50 nM PKI and
stained with cognate or irrelevant (HLA-
A2–ILAKFLHWL, hTERT) tetramer alone
or further labeled with an anti-PE 1˚ Ab 6
a PE-conjugated 2˚ Ab. The percentages of
1E6 detected above the staining with an
irrelevant tetramer are displayed for each
histogram. (C) From the same experiment
in (B), the 1E6 clone that had been cocul-
tured with K562 or K562-PPI was spiked
in to CD3/CD28-amplified PBMCs (HLA-
A2+) and then PKI treated and stained as
described in (B). The proportion of HLA-
A2–ALWGPDPAAA tetramer+ cells (gated)
from 1E6 activated with K562-PPI is
expressed as a percentage of HLA-A2–
ALWGPDPAAA tetramer+ cells (stained
with Tet + 1˚ + 2˚ Abs) from 1E6 cultured
with K562 (top panel). The gates are based
on staining with an irrelevant tetramer
(bottom panel). All cells were stained for
viability and expression of CD3 and CD8.
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the tetramer. Anti-streptavidin 1˚ Ab enhanced the MFI of tetramer
staining, although not as impressively as the anti-fluorochrome Ab
tested alongside (data not shown). The reduced effect of an anti-
streptavidin Ab compared with anti-PE Ab may reflect steric
difficulties in Ab binding to streptavidin in a PE-conjugated
pMHC tetramer. Overall, there was fluorochrome-independent
1˚ Ab-induced enhancement of tetramer staining regardless of
which anti-pMHC tetramer Ab was used. This made it more
likely that the Ab was functioning by stabilizing pMHC multi-
mer at the T cell surface during the staining protocol. We for-
mally tested this hypothesis using the PPI-specific 3F2 CD8+
T cell clone that bears an identical TCR to the 1E6 T cell clone.
T cells were stained 6 PKI with cognate and control pMHC
tetramer. Samples were fixed with PFA immediately after
staining and washed or taken through subsequent incubations
and washing steps. Surprisingly, almost half of the staining with
pMHC tetramer was lost (Fig. 8A); this loss was greatest in the
absence of PKI. In contrast, the intensity of the initial staining
was maintained in the presence of PKI and 1˚ Ab (Fig. 8). Tet-
ramer staining was completely stable when 1˚ Ab or 1˚ + 2˚ Ab
was included and cells were diluted (Fig. 8B). In contrast, al-
most half of the staining was lost in just 30 min under the
same conditions without inclusion of anti-pMHC tetramer Ab
(Fig. 8B). We also performed pMHC tetramer off rate experiments
in the presence of anti–HLA-A2 Ab to prevent rebinding of TCRs
(Fig. 8C) (12). These conditions exaggerate the dissociation of
pMHC multimer from the cell surface and showed that addition of 2˚
Ab with the 1˚ Ab did not further alter the decay rate (Fig. 8C). The
MFIs of staining in the presence of competing pMHC Ab highlighted
the differences in staining intensities over time with the different
conditions (Fig. 8D). We conclude that cross-linking of pMHC
multimer substantially reduces its dissociation from the cell surface
after staining. Presumably, this effect is also at play during regular
staining and washing protocols. Such losses could be very substantial
given that our own standard ICS protocol involves 12 washes and 3
incubation steps, thereby providing ample opportunity for pMHC
multimer staining to decrease due to dissociation from the T cell
surface. Overall, it appears that there is a large loss of tetramer from
the cell surface over time when stained cells are incubated on ice
as during most pMHC multimer, ICS, and Ab phenotyping experi-
ments. This loss can be largely prevented by stabilizing pMHC
multimer at the cell surface using anti-fluorochrome 1˚ Ab.
Discussion
Fluorescent pMHC multimers are now part of the standard toolset
for the study of Ag-specific T cells (1), but the binding affinity
threshold for staining with these tools can be significantly higher
than that required for T cell activation (2, 13). Thus, pMHC tet-
ramers fail to stain all T cells that are capable of responding to the
pMHC used in the multimer, and there is a pressing need for
reagents that can stain T cells with relatively weak affinity TCRs
such as those that predominate in cancer-specific, autoimmune, or
MHC II–restricted T cell populations. In this study, we examined
whether a combination of anti-fluorochrome unconjugated 1˚ Ab
followed by anti-Ab conjugated 2˚ Ab could be used to boost the
fluorescence signal during pMHC multimer staining and detection
by flow cytometry. Our initial experiments with the ILA1 T cell
clone and the weak 4L ligand showed that a combination of 1˚ and
2˚ Abs could boost the MFI by ∼20-fold compared with regular
tetramer staining. A 6-fold boost in fluorescence was still observed
when the staining was performed in the presence of the PKI
dasatinib that we have previously shown affords considerable
advantages during T cell staining with multimerized pMHC (1, 15,
18). Signal amplification by including a combination of 1˚ and 2˚
Abs was not wholly unexpected, although the 20-fold increase
observed was higher than expected based on calculations of how
much extra fluorochrome this procedure was expected to deliver.
We were also very surprised to observe that the majority of the
signal boost apparent with a combination of 1˚ and 2˚ Ab was still
present when only the unconjugated 1˚ Ab was used. The sub-
stantial increase in MFI observed in the presence of anti-pMHC
tetramer Ab might represent an inexpensive and easy way to in-
crease the utility of pMHC multimers and warranted further in-
vestigation. Recovery of ILA1 T cells spiked into HLA-A2+
PBMC using pMHC tetramers of the 4L, 5Y, and 8E variant that
bind with KDs of 117, ∼250, and ∼2000 mM was 6, 0.1, and 0%,
respectively, with regular tetramer staining. These levels increased
to 100, 33, and 19%, respectively, when a 1˚ Ab was included
during staining. Remarkably, all of the clone could be recovered
with pMHC tetramers of all these ligands when 1˚ Ab was in-
cluded with PKI and we were able to see effective staining of the
ILA1 T cell with the 8E variant agonist. We conclude that the
inclusion of anti-fluorochrome 1˚ Ab during pMHC tetramer
staining substantially increases both the intensity of staining and
the range of TCR–pMHC interactions that can be used to detect
T cells using these reagents. The increase in staining we observed
when an anti-pMHC multimer Ab is included is a general effect
that was also seen with other Ab clones against PE and when
allophycocyanin- or FITC-based pMHC multimers were used in
combination with Abs against the relevant fluorochrome. Inclu-
sion of 1˚ Ab during pMHC tetramer staining also enabled good
detection of T cells even when substantially less pMHC reagent
was used. The benefits of including Ab were evident when
staining T cells specific for viral, tumor, and autoimmune Ags and
with both pMHC tetramers and pMHC dextramers. There was a
distinct hierarchy of cellular recovery of antitumor T cells from a
PMBC sample that ran dextramer + 1˚ + 2˚ Abs . dextramer +
1˚ Ab . dextramer . tetramer + 1˚ + 2˚ Abs. tetramer + 1˚ Ab .
tetramer. Thus, addition of Abs against pMHC multimers during
staining improves MFI and cellular recovery with both pMHC
tetramers and pMHC dextramers. The most sensitive staining pro-
tocol used a combination of: 1) pMHC dextramer; 2) PKI; 3) anti-
fluorochrome unconjugated Ab; and 4) anti-Ab conjugated 2˚ Ab.
It is well documented that TCRs downregulate from the T cell
surface once they are triggered (34). Thus, T cells that have re-
cently engaged cognate Ag exhibit a lower surface density of TCR
and are more difficult to stain with pMHC multimers (15). This
issue becomes particularly problematic when attempting to iden-
tify self-specific T cells (anticancer or autoimmune) that tend to
bear lower affinity TCRs (3) and might be expected to have had
a reasonable chance of recent Ag encounter in vivo. When pMHC
tetramer staining ELAGIGILTV-specific T cells in the TILs ex-
panded from an HLA-A2+ patient with stage IV melanoma after
exposure to autologous tumor, 80% of the original population
could be recovered after pMHC tetramer staining with 1˚ and 2˚
Abs. This compared with just 29% with tetramer alone. Similarly,
almost all of the 1E6 PPI-specific T cells spiked into HLA-A2+
PBMC after incubation with HLA-A2+ cells expressing PPI could
be recovered using pMHC tetramer + 1˚ and 2˚ Abs, whereas none
of the cells could be recovered when stained with pMHC tetramer
alone. Thus, addition of Ab against pMHC multimers during
cellular staining can considerably improve detection of self-
specific T cells that have recently encountered Ag.
We finally examined the mechanism by which staining was
enhanced. The rational of using an unconjugated 1˚ Ab in com-
bination with a conjugated 2˚ Ab was to boost the amount of
fluorochrome that could be loaded onto Ag-specific T cells using
pMHC multimers. In some cases, this methodology increased the
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staining intensity of cognate T cells by ∼20-fold. Simple arith-
metic suggested that the additional fluorochrome added with
a combination of 1˚ and 2˚ Ab could not explain the majority of
the increase in MFI we observed. Experiments confirmed that the
majority of the increase in MFI observed with 1˚ and 2˚ Abs
during staining as described could be induced by addition of just
1˚ Ab. Further experiments showed that the enhancement afforded
by addition of Ab against pMHC tetramers extended to reagents
manufactured with allophycocyanin and FITC specificities in
addition to PE and could be induced with all Ab clones tested.
These experiments, and enhancement observed when using anti-
streptavidin Ab, rule out the possibility that our original obser-
vation was due to an Ab-induced effect on fluorochrome emission.
Instead, it seemed more likely that the major effect observed was
due to an increase in stabilization via a substantially reduced off
rate. Experiments designed to look at tetramer off rates during
standard staining incubations showed that there was a large loss of
tetramer staining during the course of experiments in the absence
of anti-pMHC tetramer Abs. Addition of an Ab against pMHC
tetramer reversed the majority of this loss.
Although the inclusion of both unconjugated 1˚ and conjugated
2˚ Abs gave the best results, our laboratory now routinely stains
using only the former Ab. Use of just 1˚ Ab provides the vast
majority of the enhancement at very little cost (,$0.25 per stain).
Addition of unconjugated 1˚ Ab does not introduce any risk of
increased background staining that is possible with the further
addition of fluorochrome-conjugated 2˚ Abs. Importantly, the
procedures described in this study have been compatible with all
of the polychromatic T cell phenotyping we have attempted to
date, providing the tetramer + 1˚ 6 2˚ Abs are applied prior to
other Abs. Nevertheless, it should be noted that anti-fluorochrome
Abs are bivalent, resulting in the potential that if one binding site
FIGURE 8. Stabilization with an anti-fluoro-
chrome Ab preserves tetramer staining at the surface
of T cells. (A) The CD8+ T cell clone 3F2 was
treated with 50 nM PKI, or left untreated, and
stained with cognate HLA-A2–ALWGPDPAAA
(from preproinsulin) PE-conjugated tetramers or ir-
relevant HLA-A2–NLVPMVTAV (from CMV) tet-
ramers. Cells were stained with tetramer alone
(gray) or tetramer with anti-PE unconjugated 1˚ Ab
(red) 6 a PE-conjugated secondary 2˚ Ab (blue).
Once stained with tetramer6 1˚ Ab 6 2˚ Ab (Start),
the cells were taken through three incubations (20
min on ice) and associated wash steps (two times)
before being analyzed (Finish). The histogram shows
the staining at the start of the assay. (B) 3F2 was
treated with PKI and stained as in (A), then diluted in
an excess volume of buffer (3 ml), and incubated at
RT for the times shown. The histogram shows the
staining at the start of the assay. (C and D) From the
same experiment in (B), cells were incubated at RT
with an anti–HLA-A2 Ab (BB7.2) in 0.1 ml of
buffer and samples taken at the times shown. Graphs
display the percentage of tetramer staining relative
to the start of the experiment for each condition (A–
C) or the MFI (C). PKI was present throughout the
assay for (B)–(D).
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were not occupied by cross-linking pMHC multimer, then it could
be available to bind Abs coupled to tandem dyes, leading to po-
tential artifacts in phenotypic measurements. Although our own
preferred staining protocol includes PKI staining and only 1˚ Ab,
all of the methodologies used in this study show additive benefits
for both the MFI of staining and the range of TCR interactions that
are amenable to detection, thereby allowing researchers to adjust
protocols to suit their own individual needs and circumstances.
In summary, we show that including Abs against pMHC tet-
ramers or dextramers during cell staining can result in substantial
improvements in both the MFI of staining and the range of TCR
interactions amenable to detection, thereby revealing important
cell populations that could not be identified otherwise. The best
results were observed with a combination of pMHC multimer,
PKI, anti-fluorochrome 1˚ Ab, and anti-Ab conjugated 2˚ Ab. Sur-
prisingly, the majority of the benefits observed with this protocol
were still evident when only the 1˚ Ab was included. In addition
to increased MFI and a weaker TCR affinity threshold required
for staining, inclusion of Ab also allowed use of log-fold lower
pMHC multimer reagent concentrations. The mechanism for these
unanticipated affects appears to involve stabilization of reagent
capture at the T cell surface during the staining protocol. We
anticipate that this improved methodology will become routinely
adopted during pMHC multimer staining, as it represents a con-
siderable improvement in the brightness of staining, an extension
in the scope of interactions that can be detected, and large po-
tential cost savings compared with existing technology.
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